A placebo controlled, double blind, randomised, 8-week phase IIa proof of concept study to assess the efficacy and safety of AKR 202 in patients with osteoarthritis pain.
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2014
Price : $35 *
At a glance
- Drugs Adefovir dipivoxil (Primary)
- Indications Osteoarthritis; Pain
- Focus Proof of concept; Therapeutic Use
- Sponsors Akron Molecules
- 22 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Dec 2013 New source identified and integrated (ClinicalTrials.gov; NCT02003118).
- 06 Nov 2013 New trial record